Last reviewed · How we verify
Estradiol+MPA
Estradiol and medroxyprogesterone acetate (MPA) together provide hormone replacement therapy by supplementing estrogen and progestin to alleviate menopausal symptoms and reduce bone loss.
Estradiol and medroxyprogesterone acetate (MPA) together provide hormone replacement therapy by supplementing estrogen and progestin to alleviate menopausal symptoms and reduce bone loss. Used for Menopausal vasomotor symptoms (hot flashes, night sweats), Vulvovaginal atrophy, Osteoporosis prevention in postmenopausal women.
At a glance
| Generic name | Estradiol+MPA |
|---|---|
| Also known as | Estradiol+medroxyprogesterone acetate |
| Sponsor | Brigham and Women's Hospital |
| Drug class | Hormone replacement therapy (HRT) |
| Target | Estrogen receptor alpha and beta; progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | FDA-approved |
Mechanism of action
Estradiol is a bioidentical estrogen that binds to estrogen receptors to restore circulating estrogen levels, while MPA is a synthetic progestin that provides endometrial protection and additional hormonal effects. Together, this combination addresses vasomotor symptoms, vaginal atrophy, and osteoporosis risk in postmenopausal women.
Approved indications
- Menopausal vasomotor symptoms (hot flashes, night sweats)
- Vulvovaginal atrophy
- Osteoporosis prevention in postmenopausal women
Common side effects
- Breast tenderness
- Vaginal bleeding or spotting
- Headache
- Nausea
- Fluid retention
- Increased risk of venous thromboembolism
- Increased risk of stroke
- Increased risk of breast cancer (with long-term use)
Key clinical trials
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (PHASE2)
- Intrauterine Stent Placement Following Hysteroscopic Septum Resection (NA)
- Estrogen Receptor Beta and Mood (PHASE2)
- Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency (NA)
- Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women (PHASE2)
- Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery (PHASE3)
- A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment
- HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estradiol+MPA CI brief — competitive landscape report
- Estradiol+MPA updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI